Commentary on payment and reimbursement issues affecting the marketing of drugs, medical devices, and biologics, with emphasis on the anti-kickback statute and Stark II.
Reiss
J B
JB
Saul, Ewing, Remick & Saul, Philadelphia, PA, USA.
D016265:Conflict of Interest / Q000331:legislation & jurisprudence; D004345:Drug Industry / Q000191:economics / Q000331:legislation & jurisprudence; D004864:Equipment and Supplies / Q000191:economics* / Q000592:standards; D005607:Fraud / Q000331:legislation & jurisprudence*; D006801:Humans; D019458:Insurance Coverage / Q000191:economics* / Q000331:legislation & jurisprudence; D007883:Legislation, Medical; D008389:Marketing of Health Services / Q000191:economics / Q000331:legislation & jurisprudence*; D006278:Medicare / Q000191:economics; D012051:Reimbursement Mechanisms / Q000191:economics* / Q000331:legislation & jurisprudence*; D014481:United States